RT @JohnEbbenMDPhD
A huge thank you to @shafiarahman_ & @RischZack for presenting us with the latest data in #EGFR targeting in #metastatic #ColorectalCancer.

Excited to see how 🩸🧬#ctDNA can help us design rational strategies to better use EGFR therapies particularly with re-challenge. https://twitter.com/JohnEbbenMDPhD/status/1639072110139125761

RT @JohnEbbenMDPhD
A huge thank you to @shafiarahman_ & @RischZack for presenting us with the latest data in #EGFR targeting in #metastatic #ColorectalCancer.

Excited to see how 🩸🧬#ctDNA can help us design rational strategies to better use EGFR therapies particularly with re-challenge. https://twitter.com/JohnEbbenMDPhD/status/1639072110139125761

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ @ASCO 4/22 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 2👨🏻‍🏫

📌RAS Mutation = resistance to anti-EGFR therapy

📌KRAS muts:🕵🏻 detected by NGS- tissue or liquid bx #ctDNA

≈49% of #CRC= KRAS/NRAS muts
KRAS codons 12 (30%) & 13 (~8%) of exon 2. NRAS (exons 2, 3, 4)
📚https://pubmed.ncbi.nlm.nih.gov/26189770/

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ @ASCO 4/22 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 2👨🏻‍🏫

📌RAS Mutation = resistance to anti-EGFR therapy

📌KRAS muts:🕵🏻 detected by NGS- tissue or liquid bx #ctDNA

≈49% of #CRC= KRAS/NRAS muts
KRAS codons 12 (30%) & 13 (~8%) of exon 2. NRAS (exons 2, 3, 4)
📚https://pubmed.ncbi.nlm.nih.gov/26189770/

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ @ASCO 4/22 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 2👨🏻‍🏫

📌RAS Mutation = resistance to anti-EGFR therapy

📌KRAS muts:🕵🏻 detected by NGS- tissue or liquid bx #ctDNA

≈49% of #CRC= KRAS/NRAS muts
KRAS codons 12 (30%) & 13 (~8%) of exon 2. NRAS (exons 2, 3, 4)
📚https://pubmed.ncbi.nlm.nih.gov/26189770/

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ @ASCO 4/22 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 2👨🏻‍🏫

📌RAS Mutation = resistance to anti-EGFR therapy

📌KRAS muts:🕵🏻 detected by NGS- tissue or liquid bx #ctDNA

≈49% of #CRC= KRAS/NRAS muts
KRAS codons 12 (30%) & 13 (~8%) of exon 2. NRAS (exons 2, 3, 4)
📚https://pubmed.ncbi.nlm.nih.gov/26189770/

RT @JohnEbbenMDPhD
A huge thank you to the one and only @DrSteveMartin & @DAielloMD for bringing us the #MarchMadness of #NSCLC and exploring how #ctDNA will change practice! I'm looking forward to that baklava! https://twitter.com/JohnEbbenMDPhD/status/1634012967149920257

RT @TumorBoardTues
#TumorBoardTuesday

🧬@DrSteveMartin @DAielloMD brought a March Madness worthy set of cases that illustrate how #ctDNA is being used in #NSCLC.

➡️Here’s the Case 🎀
👉🆓#CME credit by answering 2 quick ❓
ALL CME 🔗: http://integrityce.com/tbt
CME eval🔗: http://integrityce.com/tbteval

#TumorBoardTuesday

🧬@DrSteveMartin @DAielloMD brought a March Madness worthy set of cases that illustrate how #ctDNA is being used in #NSCLC.

➡️Here’s the Case 🎀
👉🆓#CME credit by answering 2 quick ❓
ALL CME 🔗: http://integrityce.com/tbt
CME eval🔗: http://integrityce.com/tbteval

RT @FawziAbuRous
Best GIFt from the #meme king and #TumorBoardTuesday guru @DrSteveMartin
Very enjoyable and educational session on #ctDNA by @DAielloMD
@TumorBoardTues

RT @FawziAbuRous
@DrSteveMartin @JohnEbbenMDPhD @GDutcherMD @DAielloMD Loving this March Madness #ctDNA #TumorBoardTuesday!!

RT @pashtoonkasi
🆕Published today🗞️
@ASCO #ASCODailyNews

“Utility & Debate of #LiquidBiopsies in Surveillance Setting”

The❓of what go do if someone is #ctDNA➕. My 2 cents👇🏾.

💡Adjuvant-Plus or #MRD-plus setting➡️🆕platform for trials.

@OncoAlert @DrawImpacts

Link: https://dailynews.ascopubs.org/do/utility-and-debate-liquid-biopsy-assays-surveillance-setting#.ZAkizbGuXdg.twitter

RT @anmwongNZ
Check out #TumorBoardTuesday
great learning! 🙏

Deep dive into #ctdna in lung cancer #LCSM 🧬🫁

Tests seldomly used in NZ due to high💰and lack of 💊access

💪Let’s change this

@Mal_Itchins @TOGAANZ @NzsOncology @cancer_agency @cameroncologist @sandrajfitz https://twitter.com/daiellomd/status/1633271395550412800

RT @anmwongNZ
Check out #TumorBoardTuesday
great learning! 🙏

Deep dive into #ctdna in lung cancer #LCSM 🧬🫁

Tests seldomly used in NZ due to high💰and lack of 💊access

💪Let’s change this

@Mal_Itchins @TOGAANZ @NzsOncology @cancer_agency @cameroncologist @sandrajfitz https://twitter.com/daiellomd/status/1633271395550412800

RT @anmwongNZ
Check out #TumorBoardTuesday
great learning! 🙏

Deep dive into #ctdna in lung cancer #LCSM 🧬🫁

Tests seldomly used in NZ due to high💰and lack of 💊access

💪Let’s change this

@Mal_Itchins @TOGAANZ @NzsOncology @cancer_agency @cameroncologist @sandrajfitz https://twitter.com/daiellomd/status/1633271395550412800

RT @CharuAggarwalMD
@DrSteveMartin @TumorBoardTues @MPishvaian @DAielloMD @JohnEbbenMDPhD @ChristianRolfo Almost all my patients get concurrent tissue and plasma testing upon initial diagnosis #ctDNA @DrSteveMartin

RT @FawziAbuRous
@DrSteveMartin @TumorBoardTues @DAielloMD Failed the #ctDNA test so I needed a different way to get dessert!

RT @CharuAggarwalMD
@DrSteveMartin @TumorBoardTues @MPishvaian @DAielloMD @JohnEbbenMDPhD @ChristianRolfo Given that oncogenic drivers are mutually exclusive (majority of the time), finding of a non-actionable mutation such as KRAS G12D can be immensely meaningful, to begin therapy which is #MolecularlyInformed #ctDNA

RT @CharuAggarwalMD
@DrSteveMartin @TumorBoardTues @MPishvaian @DAielloMD @JohnEbbenMDPhD @ChristianRolfo Almost all my patients get concurrent tissue and plasma testing upon initial diagnosis #ctDNA @DrSteveMartin

RT @JohnEbbenMDPhD
It's TIME! Follow the thread below as #TumorBoardTuesday, led by @DrSteveMartin & @DAielloMD discuss real 🌎 examples of #ctDNA use in #NSCLC. Can't wait to learn 📚 from these cases! https://twitter.com/DAielloMD/status/1633271395550412800